Hongming Pan

23.5k total citations · 6 hit papers
222 papers, 9.2k citations indexed

About

Hongming Pan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hongming Pan has authored 222 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 127 papers in Oncology, 92 papers in Pulmonary and Respiratory Medicine and 68 papers in Molecular Biology. Recurrent topics in Hongming Pan's work include Lung Cancer Treatments and Mutations (49 papers), Colorectal Cancer Treatments and Studies (48 papers) and Cancer Immunotherapy and Biomarkers (45 papers). Hongming Pan is often cited by papers focused on Lung Cancer Treatments and Mutations (49 papers), Colorectal Cancer Treatments and Studies (48 papers) and Cancer Immunotherapy and Biomarkers (45 papers). Hongming Pan collaborates with scholars based in China, United States and Taiwan. Hongming Pan's co-authors include Weidong Han, Xinbing Sui, Ju-Jun Xie, Na Kong, Chao He, Xian Wang, Jichun Zhou, Li Ye, Qin Zhang and Liangkun You and has published in prestigious journals such as Advanced Materials, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hongming Pan

220 papers receiving 9.1k citations

Hit Papers

Autophagy and chemotherap... 2013 2026 2017 2021 2013 2013 2015 2014 2015 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment
    2013 1.0k citations Xinbing Sui, Na Kong et al. profile →
  2. p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents
    2013 815 citations Xinbing Sui, Na Kong et al. Cancer Letters profile →
  3. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
    2015 553 citations Shukui Qin, Rui‐Hua Xu et al. profile →
  4. Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
    2014 465 citations Shukui Qin, Hongming Pan et al. Journal of Clinical Oncology profile →
  5. The role of STAT3 in autophagy
    2015 418 citations Liangkun You, Ju-Jun Xie et al. profile →
  6. CD3+CD4-CD8- (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer
    2022 146 citations Hongming Pan et al. Frontiers in Immunology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Hongming Pan 3.8k 3.1k 2.3k 1.8k 1.8k 222 9.2k
Lixin Wei 4.1k 1.1× 2.4k 0.8× 2.1k 0.9× 942 0.5× 2.0k 1.1× 244 9.1k
Hirohisa Yano 3.1k 0.8× 2.4k 0.8× 1.0k 0.4× 974 0.5× 1.7k 1.0× 283 8.0k
Hitoshi Yoshiji 3.7k 1.0× 2.2k 0.7× 3.3k 1.4× 897 0.5× 2.3k 1.3× 365 10.9k
Xin Chen 6.6k 1.7× 2.2k 0.7× 1.1k 0.5× 1.1k 0.6× 3.2k 1.8× 382 11.7k
Beicheng Sun 4.7k 1.2× 1.9k 0.6× 1.5k 0.7× 611 0.3× 3.0k 1.7× 177 8.7k
Hiroaki Nagano 5.0k 1.3× 4.2k 1.4× 2.2k 1.0× 1.7k 0.9× 3.2k 1.8× 451 13.1k
Hui Zhang 6.7k 1.8× 1.7k 0.5× 2.2k 0.9× 797 0.4× 4.0k 2.3× 359 10.9k
Ya Cao 7.2k 1.9× 3.9k 1.3× 1.3k 0.6× 1.9k 1.0× 4.7k 2.7× 311 12.6k
Weijing Sun 2.2k 0.6× 4.5k 1.5× 860 0.4× 1.4k 0.8× 1.3k 0.7× 199 7.9k
Antonio Russo 4.7k 1.2× 5.8k 1.9× 768 0.3× 2.3k 1.3× 3.2k 1.8× 371 11.9k

Countries citing papers authored by Hongming Pan

Since Specialization
Citations

This map shows the geographic impact of Hongming Pan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongming Pan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongming Pan more than expected).

Fields of papers citing papers by Hongming Pan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hongming Pan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongming Pan. The network helps show where Hongming Pan may publish in the future.

Co-authorship network of co-authors of Hongming Pan

This figure shows the co-authorship network connecting the top 25 collaborators of Hongming Pan. A scholar is included among the top collaborators of Hongming Pan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hongming Pan. Hongming Pan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yang, Pan, et al.. (2024). Exploration and machine learning model development for T2 NSCLC with bronchus infiltration and obstructive pneumonia/atelectasis. Scientific Reports. 14(1). 4793–4793. 1 indexed citations
2.
Pan, Hongming, Jean Frédéric Blanc, Véronique Grando, et al.. (2024). Activity of Tepotinib in Hepatocellular Carcinoma With High-Level MET Amplification: Preclinical and Clinical Evidence. JCO Precision Oncology. 8(8). e2300328–e2300328. 6 indexed citations
3.
Lee, Chien‐Chang, Ye Liu, Hongming Pan, et al.. (2024). GRADE-based procalcitonin guideline for emergency departments. The American Journal of Emergency Medicine. 89. 109–123. 5 indexed citations
4.
5.
6.
Zhao, Jun, Xinmin Yu, Dingzhi Huang, et al.. (2023). SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 11(2). e006055–e006055. 15 indexed citations
7.
Guo, Ye, Zishu Wang, Huan Zhou, et al.. (2023). GFH018, a small molecular inhibitor targeting TGF-βRI kinase, in patients with advanced solid tumors: Final results of the phase I study.. Journal of Clinical Oncology. 41(16_suppl). e15117–e15117. 2 indexed citations
8.
Zhu, Andrew X., Farshid Dayyani, Chia‐Jui Yen, et al.. (2022). Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. Clinical Cancer Research. 28(16). 3537–3545. 75 indexed citations
9.
Si, Lu, Xiaoshi Zhang, Yongqian Shu, et al.. (2022). Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study. Frontiers in Immunology. 13. 882471–882471. 18 indexed citations
10.
Liu, Lili, Hua Jiang, Hongming Pan, & Xiuming Zhu. (2021). LncRNA XIST promotes liver cancer progression by acting as a molecular sponge of miR-200b-3p to regulate ZEB1/2 expression. Journal of International Medical Research. 49(5). 3619077139–3619077139. 20 indexed citations
11.
Ryoo, Baek‐Yeol, Ann‐Lii Cheng, Zhenggang Ren, et al.. (2021). Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. British Journal of Cancer. 125(2). 200–208. 36 indexed citations
12.
13.
Cen, Shuyi, Zhen Liu, Hongming Pan, & Weidong Han. (2021). Clinicopathologic features and treatment advances in cancers with HER2 alterations. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1876(2). 188605–188605. 12 indexed citations
14.
Pan, Hongming, Huanqing Cheng, Huina Wang, et al.. (2021). Molecular profiling and identification of prognostic factors in Chinese patients with small bowel adenocarcinoma. Cancer Science. 112(11). 4758–4771. 8 indexed citations
15.
Tong, Mengting, Jing Wang, Wenting He, et al.. (2018). Predictive biomarkers for tumor immune checkpoint blockade. Cancer Management and Research. Volume 10. 4501–4507. 15 indexed citations
16.
Tan, Peng, Youqiong Ye, Lian He, et al.. (2018). TRIM59 promotes breast cancer motility by suppressing p62-selective autophagic degradation of PDCD10. PLoS Biology. 16(11). e3000051–e3000051. 75 indexed citations
17.
Xu, Rui‐Hua, Jin Li, Yuxian Bai, et al.. (2017). Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. Journal of Hematology & Oncology. 10(1). 63 indexed citations
18.
Fang, Yong, Xiaoyun Zhou, Lili Liu, et al.. (2017). Relationship of metformin with the risk of pancreatic cancer in patients with type 2 diabetes: a meta-analysis. Biomedical Research-tokyo. 28(10). 4439–4444. 3 indexed citations
19.
Lou, Haizhou, Hongming Pan, Pan Qin, et al.. (2014). The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells. Biochemical and Biophysical Research Communications. 450(2). 973–978. 25 indexed citations
20.
Sui, Xinbing, Na Kong, Li Ye, et al.. (2013). p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Letters. 344(2). 174–179. 815 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lixin Wei Breakdown of academic impact, for papers by Hirohisa Yano Breakdown of academic impact, for papers by Hitoshi Yoshiji Breakdown of academic impact, for papers by Xin Chen Breakdown of academic impact, for papers by Beicheng Sun Breakdown of academic impact, for papers by Hiroaki Nagano Breakdown of academic impact, for papers by Hui Zhang Breakdown of academic impact, for papers by Ya Cao Breakdown of academic impact, for papers by Weijing Sun Breakdown of academic impact, for papers by Antonio Russo
Rankless by CCL
2026